NEW YORK (GenomeWeb) — RxGenomix has partnered with Coriell Life Sciences (CLS) to offer a pharmacogenomics training, implementation, and management package to healthcare providers, the companies said today.
Under the terms of the alliance, the firms will combine Franklin, Tennessee-based RxGenomix's pharmacogenomics training and implementation program with CLS' bioinformatic services for risk analysis, reporting, and population-level healthcare analytics.
Additional terms were not disclosed.
"CLS brings the right mix of analytics capabilities along with rich scientific decision support, which accelerates RxGenomix's ability to deploy the most comprehensive and effective PGx offering in healthcare," RxGenomix COO Blake Keller said in a statement.
In late 2017, Philadelphia-based CLS signed an agreement with Ovation to integrate their respective data management and reporting technologies into a single platform.